Abstract | INTRODUCTION: Hypervolemia and hyponatremia are common features in heart failure and have been associated with increased morbidity and mortality. Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan is a selective vasopressin type 2 (V(2)) receptor antagonist that has been demonstrated to have the ability to induce aquaresis, the electrolyte sparing excretion of water, resulting in fluid removal as well as correction of hyponatremia. AREAS COVERED: EXPERT OPINION: The available experience of lixivaptan in heart failure, although limited, is encouraging. Its aquaretic effect provides the basis for its use to correct hypervolemia and hyponatremia in patients with heart failure, and the absence of neurhormonal stimulation provides positive signal for the exploration of its potential in improving outcomes.
|
Authors | Hammam D Zmily, Nazia S Khan, Suleiman Daifallah, Jalal K Ghali |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 20
Issue 6
Pg. 831-48
(Jun 2011)
ISSN: 1744-7658 [Electronic] England |
PMID | 21548825
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antidiuretic Hormone Receptor Antagonists
- Benzamides
- Pyrroles
- Arginine Vasopressin
- lixivaptan
|
Topics |
- Animals
- Antidiuretic Hormone Receptor Antagonists
- Arginine Vasopressin
(metabolism)
- Benzamides
(adverse effects, pharmacokinetics, pharmacology)
- Heart Failure
(drug therapy, physiopathology)
- Humans
- Hyponatremia
(drug therapy, etiology)
- Plasma Volume
(drug effects)
- Pyrroles
(adverse effects, pharmacokinetics, pharmacology)
|